Cystatin C for gentamicin dosing - a case study

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F27661989%3A_____%2F25%3A10002859" target="_blank" >RIV/27661989:_____/25:10002859 - isvavai.cz</a>
Result on the web
<a href="https://www.biochemia-medica.com/en/journal/35/3/10.11613/BM.2025.030902" target="_blank" >https://www.biochemia-medica.com/en/journal/35/3/10.11613/BM.2025.030902</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.11613/BM.2025.030902" target="_blank" >10.11613/BM.2025.030902</a>

Result language
angličtina
Original language name
Cystatin C for gentamicin dosing - a case study
Original language description
The study aims to present a case study of a patient with supratherapeutic serum gentamicin concentration. An 83-year-old male was admitted to the Department of Internal Medicine for persistent loss of appetite, decompensated heart failure, and pneumonia. He was treated with 240 mg gentamicin daily alongside ampicillin/sulbactam penicillin antibiotic. The trough gentamicin concentrations and estimated glomerular filtration rate from creatinine (eGFRcrea) and cystatin C (eGFRcys) were performed. The patient had the supratherapeutic trough gentamicin concentration of 2.5 mg/L. eGFRcrea was 62 mL/min/1.73m2 and eGFRcys was 25 mL/min/1.73m2. The difference between eGFRcrea and eGFRcys was 148%. Falsely high eGFRcrea in elderly patient led to the supratherapeutic gentamicin concentration even after the standard 240 mg gentamicin dose.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30230 - Other clinical medicine subjects

Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)